Liver Disease Treatment Market Insight 2030
The global liver disease treatment market size was valued at $20,673.70 million in 2020, and is estimated to reach $36,455.70 million by 2030, growing at a CAGR of 5.7% from 2021 to 2030. Liver is the largest solid organ and largest gland in the human body. In addition, it suffers from various ailments, which are treated using different types of products. In addition, these products include different kinds of drugs and vaccines. For instance, anti-viral drugs are used to treat hepatitis that cause liver inflammation. In addition, hepatitis is fatal, and thus sometimes requires liver transplant. In such cases, immunosuppressant drugs that prevent rejection of transplanted liver in the body are used.
Furthermore, immunoglobulin is used in treatment of certain types of hepatitis. Moreover, vaccines are used to prevent hepatitis viral infection. For instance, vaccines are available for prevention of hepatitis A, B, and C. Furthermore, other products such as corticosteroids are used in the treatment of liver related autoimmune diseases such as autoimmune hepatitis. Thus, there are various liver related conditions such as hepatitis, autoimmune diseases, non-alcoholic fatty liver, cancer, and genetic disorders, which are treated by using different types of products such as anti-viral drugs, immunosuppressants, vaccines immunoglobulins, corticosteroids, targeted therapy, and chemotherapy.
Increase in prevalence of liver diseases such as the non-alcoholic fatty liver disease (NAFLD), liver cirrhosis, hepatitis, alcoholic hepatitis, and liver cancer, globally is majorly due to unhealthy lifestyle and alcohol consumption. In addition, rise in geriatric population globally further leads to disease dysfunction. Thus, there has been an increase in hospital admissions due to various abovementioned liver diseases as well certain genetic disorders, which are hereditary.
Considerable rise in alcohol consumption is one of the major reasons that leads to liver disorders, as some liver cells die as a result of the alcohol filtering process, thus leading to scar tissue build up in the liver. Although the liver can regenerate new cells, heavy drinking can impair this function and may lead to permanently damage. Alcohol-related liver disease also known as alcoholic liver disease is a phrase for three liver diseases linked to heavy drinking: alcoholic fatty liver, alcoholic hepatitis, and alcoholic cirrhosis.
In addition, poor eating habits and unhealthy lifestyle causes weight gain further leading to obesity. Obesity, followed by alcoholism, is the major cause of fatty liver disease in adults. Fat accumulates in the liver as a result of being overweight or obese. This causes liver scarring and chronic inflammation (also known as cirrhosis). Obesity is closely associated to non-alcoholic fatty liver disease. Insulin resistance and inflammatory signals are caused by excess fat. Fatty liver disease is more likely to occur in patients who have hypertension (high blood pressure), high cholesterol, are overweight or obese, and have diabetes or insulin resistance. However, stringent regulatory approvals for novel drugs & vaccines and resistance to certain antiviral drugs restrain the market growth.
Furthermore, geriatric population is more prone to liver diseases compared to adults, owing to their low immunity levels. In addition, ageing has been shown to enhance vulnerability to acute liver injury. Initiatives taken by various governments, not-for-profit organizations, key players of the market for hepatic disorders play a pivotal role in increasing awareness about liver diseases around the world.
Thus, all these factors collectively provide opportunity for investments in R&D activities for the development of liver disease treatment solutions for better drug efficacy and safe therapy for already existing drugs as well as upcoming new molecular entities, which further drives the growth of the liver disease treatment market.
What is the Impact of COVID-19 Pandemic on the Liver Disease Treatment Market?
In addition, the COVID-19 outbreak is anticipated to have a moderate impact, owing to decline in demand for various drugs used in liver treatments. Furthermore, other factors responsible for the impact on the market include limited availability of medical care, shortage of healthcare staff, rise in burden of COVID-19 related hospitalization, and availability of drugs and vaccines. However, as the vaccinations for COVID-19 are available various governments are working to ensure undisrupted supply of life saving drugs and vaccines. Thus, this is expected to lead to a stabilization in the market overtime
Conversely, research studies and activities, including clinical trials for the efficacy and safety, for the treatment of liver disease by various researchers, companies, and government boosted the liver disease treatment market.
Furthermore, untapped, emerging markets are expected to offer potential growth opportunities, due to improved healthcare infrastructure, increase in unmet healthcare needs, and rise in R&D activities. In addition, various technological advancements in drug delivery is an emerging opportunity for key players to invest in the liver disease treatment market.
By Treatment Type
Antiviral Drugs holds a dominant position in 2020 and would continue to maintain the lead over the forecast period.
Liver Disease Treatment Market Segmentation
The global liver disease treatment market is segmented into treatment type, disease type, and region. On the basis of treatment, the market is segregated into antiviral drugs, immunosuppressants, vaccines, immunoglobulins, corticosteroids, targeted therapy, and chemotherapy drugs.
By disease type, the market is segmented into hepatitis, autoimmune diseases, non-alcoholic fatty liver disease (NAFLD), cancer, genetic disorders, and others.
Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
By Disease Type
Hepatitis segment is projected as one of the most lucrative segment.
Segment review
Depending on the treatment type, the antiviral drugs segment dominated the market in 2020, and is expected to continue this trend during the forecast period, due to increase in prevalence of viral liver diseases.
By disease type, the hepatitis segment exhibited the highest growth in 2020, and is expected to continue this trend during the forecast period.
North America accounted for a majority of the global liver disease treatment market share in 2020, and is anticipated to remain dominant during the forecast period. This is attributed to increase in consumption of alcohol, unhealthy lifestyle leading to obesity & weight gain, presence of key players, and rise healthcare expenditure in the region. However, Asia-Pacific is anticipated to witness notable growth, owing to rise in R&D activities, surge in liver diseases, unmet medical demands, and increase in investments in the healthcare sector in the region.
By Region
Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 7.80% during the forecast period.
Key Benefits for Stakeholders
- The study provides an in-depth analysis of the liver disease treatment market, and the current trends and future estimations to elucidate the imminent investment pockets.
- It presents a quantitative analysis of the liver disease treatment market from 2021 to 2030 to enable stakeholders to capitalize on the prevailing market opportunities.
- Extensive analysis of the market based on procedures and services assists to understand the trends in the industry.
- Key players and their strategies are thoroughly analyzed to understand the competitive outlook of the liver disease treatment market.
Liver Disease Treatment Market Report Highlights
| Aspects | Details |
 By TREATMENT TYPE |
|
 By DISEASE TYPE |
|
 By Region |
|
 Key Market Players | ABBVIE INC., MERCK & CO. INC., VIATRIS INC., F. HOFFMANN-LA ROCHE AG, ABBOTT LABORATORIES, BRISTOL-MYERS SQUIBB, ELI LILLY AND COMPANY, EMERGENT BIOSOLUTIONS INC. (CANGENE BIOPHARMA), GILEAD SCIENCES, INC., ASTELLAS PHARMA INC. |
Analyst Review
This section provides the opinions of the top level CXOs in the global liver disease treatment market. According to the insights of CXOs, increase in geriatric population, increased alcohol consumption, unhealthy lifestyle, unhealthy eating habits leading to obesity, all leading to wide range of liver disorders are expected to significantly boost the growth of the liver disease treatment market.
The CXOs further added that increase in prevalence of chronic diseases which affects the liver, surge in liver cancer cases, and global rise of hepatitis cases escalate the growth of the market. Moreover, rise in drug discovery & development and introduction of novel drugs for the treatment of liver diseases notably contribute toward the growth of the market.
Furthermore, experts of key companies believe surge in geriatric population, which is more prone to liver diseases, rise in awareness toward early detection and treatment of liver diseases, and increase in government programs designed to spread awareness related to hepatitis prevention fuel the growth of the liver disease treatment market.
The market gains interest of healthcare companies, owing to surge in R&D and increase in focus in adoption of liver disease treatment in research centers.
North America is expected to witness highest growth, in terms of revenue, owing to increase in prevalence of chronic diseases, rise in consumption of alcohol, unhealthy lifestyle leading to obesity and weight gain, presence of key players, and rise healthcare expenditure in the region. However, Asia-Pacific is anticipated to witness notable growth, owing to rise in R&D activities leading to clinical trials for various diseases, surge in liver diseases, unmet medical demands, and due to the continuous government support for pharmaceutical and biotechnology R&D, increase in public–private investments, and rise in number of translational research activities in the healthcare sector.
The total market value of liver disease treatment market is $20,673.70 million in 2020.
The forecast period for liver disease treatment market is 2021 to 2030
The market value of liver disease treatment market in 2021 is $22,100.20 million.
The base year is 2020 in liver disease treatment market
Top companies such as AbbVie Inc., Abbott Laboratories, Astellas Pharma Inc., Bristol Myers Squibb, Eli Lilly and Company, F. Hoffman-LA Roche, Emergent BioSolutions (Cangene bioPharma), Gilead Sciences, Inc., Merck & Co., Inc. (Merck Sharp & Dohme Corp.) and Viatris Inc., held a high market position in 2020.
Antiviral drugs segment dominated the global market in 2020, and expected to continue this trend throughout the forecast period due to their increase in prevalence of virus infected liver diseaes, specifically surge of hepatitis cases is expected to drive the segment
Increase in prevalence of liver diseases, increase in alcohol consumption, advanced infrastructure for research & development and investments in healthcare is anticipated to drive the market in the forecast period.
North America is projected to account for a major share of the global liver disease treatment market during the forecast period. Asia-Pacific is projected to offer lucrative oppurtunities due to increase in prevalence of liver diseases, rise in investments for drug discovery in the R & D sector due to presence of key players across the region.
Loading Table Of Content...
